# Do You Need a Healthcare-Specific Due-Diligence Platform? A Practical Answer for Healthcare Investors > Generic due-diligence tools miss the regulatory, clinical, and IP signals that make or break healthcare investments. This explainer explains exactly why healthcare-specific due diligence matters and what to look for in a purpose-built platform. ## Do You Actually Need a Healthcare-Specific Due-Diligence Platform? Yes, and the gap between generic and healthcare-specific due diligence is wide enough to cost you a deal or a portfolio company. Healthcare investments fail or succeed on signals that general financial platforms were never designed to read: FDA action letters, clinical trial endpoint choices, patent expiry cliffs, CMS reimbursement coding changes, and HIPAA compliance posture. Missing any one of these can turn a promising asset into a write-down. A healthcare-specific platform is not a luxury for large funds. It is the baseline for anyone deploying capital into biotech, medtech, digital health, or healthcare services. ## What Makes Healthcare Due Diligence Categorically Different? Healthcare due diligence requires simultaneous fluency across at least five distinct data universes that have almost no overlap with standard corporate finance analysis. First, regulatory status is a live variable. An FDA Complete Response Letter, a Warning Letter posted to the FDA database, or a clinical hold on ClinicalTrials.gov can wipe out the investment thesis overnight. These documents are publicly available but scattered, time-stamped differently, and easy to miss unless you are monitoring them in near real time. Second, clinical evidence quality determines commercial potential in ways that revenue projections alone cannot capture. A Phase 2 trial with a surrogate endpoint and a small sample size is a fundamentally different risk profile than a Phase 3 trial with a hard endpoint and pre-specified secondary outcomes. Reading those distinctions requires PubMed literacy and protocol-level analysis, not just a financial model. Third, intellectual property in healthcare is unusually fragile. A compound patent, a device claim, and a method-of-use patent all expire on different schedules and face different inter partes review risks at the USPTO. Orange Book listings for drugs, 510(k) clearance records, and PMA supplements all interact with IP in ways that determine exclusivity windows and competitive moats. Fourth, reimbursement is a revenue driver that has no analogue in most other industries. A product with no assigned CPT code or a J-code pending at CMS is commercially stranded regardless of clinical performance. Checking reimbursement status requires cross-referencing CMS coverage databases, local coverage determinations, and payer policy bulletins. Fifth, healthcare entities carry compliance obligations under HIPAA, OIG exclusion lists, and state licensure frameworks that create material liability exposure invisible to a generic due-diligence checklist. ## What Primary Sources Should Every Healthcare Investor Be Checking? A credible healthcare due-diligence process pulls from at least these primary sources directly rather than relying on summaries. - FDA Drugs database and device 510(k)/PMA databases at fda.gov for clearance and approval history - FDA Warning Letters and Establishment Inspection Reports for quality system risk - ClinicalTrials.gov for trial status, enrollment numbers, primary endpoints, and sponsor-reported results - SEC EDGAR for 10-K and 10-Q risk factor disclosures, especially forward-looking statements about regulatory milestones - USPTO Patent Center and the Orange Book for IP coverage and expiry timelines - PubMed for peer-reviewed efficacy and safety data independent of company-sponsored communications - CMS Coverage Database and the Medicare Physician Fee Schedule for reimbursement status - OIG List of Excluded Individuals and Entities for compliance screening of key personnel and corporate entities The problem is that pulling and synthesizing all of this manually for a single target company takes an experienced analyst 30 to 60 hours per deal. For a fund with a high deal volume that timeline is a bottleneck, and for a smaller fund or family office it is often simply skipped. ## Where Generic Platforms Fall Short Platforms built for broad corporate due diligence handle financial statements, cap table analysis, and litigation searches well. They are not built to flag that a device company's 510(k) was cleared on a predicate that later received a Safety Communication, or that a biotech's lead program has a ClinicalTrials.gov record showing a primary completion date that passed two years ago with no posted results. Those are the signals that predict regulatory risk and pipeline credibility, and they require domain-specific parsing logic and healthcare-native data pipelines to surface automatically. ## What a Healthcare-Specific Platform Should Actually Do When evaluating any healthcare-specific due-diligence platform, require that it does the following without manual prompting. - Pulls and parses FDA action history including Warning Letters, 483 observations, and hold notices - Monitors ClinicalTrials.gov for status changes, endpoint modifications, and unreported results - Cross-references patent expiry against clinical and regulatory timelines to identify exclusivity cliffs - Flags OIG exclusion matches against leadership and corporate entity names - Maps CPT and HCPCS reimbursement codes to determine commercial readiness - Links SEC EDGAR filings to verify that management representations match public disclosures - Provides direct source citations so you can audit the underlying primary document, not just a summary ## Healthcare Due-Diligence Checklist (Pre-Term Sheet Minimum) - [ ] FDA approval, clearance, or de novo status confirmed with current adverse action screen - [ ] ClinicalTrials.gov record reviewed for endpoint integrity and completion status - [ ] Key patents identified with expiry dates and active litigation or IPR proceedings noted - [ ] Orange Book or device predicate chain verified - [ ] CMS reimbursement code assigned and coverage policy confirmed - [ ] OIG exclusion check run on CEO, CMO, board members, and the entity itself - [ ] SEC EDGAR risk factors reviewed for regulatory milestone dependencies - [ ] PubMed search run for independent peer-reviewed evidence ## How MedFuel Intel Closes the Gap MedFuel Intel was built specifically for this workflow. Its AI due-diligence engine monitors and parses FDA, ClinicalTrials.gov, USPTO, CMS, EDGAR, and OIG data simultaneously, generates structured reports with primary-source citations, and flags contradictions between company claims and public records before you sign a term sheet. Every finding links back to the original document so your legal and clinical advisors can verify independently. Run a free Red Flag Screener on any healthcare target today at https://medfuelintel.com and see what a generic platform would have missed. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/do-you-need-a-healthcare-specific-due-diligence-platform). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.